

Resource Summary Report

Generated by [Kravitz](#) on Sep 16, 2026

Fatty Liver Inhibition of Progression (FLIP)

RRID:SCR_013702

Type: Tool

Proper Citation

Fatty Liver Inhibition of Progression (FLIP) (RRID:SCR_013702)

Resource Information

URL: <http://www.flip-fp7.eu/>

Proper Citation: Fatty Liver Inhibition of Progression (FLIP) (RRID:SCR_013702)

Description: The Fatty Liver: Inhibition of Progression consortium (FLIP) aims to study the mechanisms of progression of liver disease in NAFLD to provide strategies for prevention and therapy. The project is based on the largest European cohort of patients with histologically diagnosed NAFLD, assembled with clinical and epidemiological data, and with biobanks of DNA, frozen liver tissue and serum. The consortium's efforts span all the steps of the disease for studying cellular mechanisms of progression, with a goal of answering key issues dealing with the interplay of metabolic, inflammatory and fibrotic factors in the initiation and perpetuation of liver injury.

Abbreviations: FLIP

Resource Type: consortium, data or information resource, organization portal, portal

Keywords: basic science, basic research, data-sharing enabler, liver, NAFLD,

Funding: European Union FP7

Resource Name: Fatty Liver Inhibition of Progression (FLIP)

Resource ID: SCR_013702

Record Creation Time: 20220129T080317+0000

Record Last Update: 20260912T195807+0000

Ratings and Alerts

No rating or validation information has been found for Fatty Liver Inhibition of Progression (FLIP).

No alerts have been found for Fatty Liver Inhibition of Progression (FLIP).

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [Kravitz](#) .

Poynard T, et al. (2018) Impact of steatosis and inflammation definitions on the performance of NASH tests. European journal of gastroenterology & hepatology, 30(4), 384.

Munteanu M, et al. (2016) Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Alimentary pharmacology & therapeutics, 44(8), 877.

Gallego-Dur??n R, et al. (2016) Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease. Scientific reports, 6, 31421.